PMH Laboratory INC

PMH Laboratory INC was paid $17.09M by Medicaid between Jul 2019 and Nov 2024, across 23 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 69% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#52 of 561

Median peer was paid$222K

This provider vs. median77×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	478	$3K
2020	33,542	$1.12M
2021	263,383	$5.74M
2022	391,203	$9.06M
2023	38,020	$1.16M
2024incomplete	1,570	$16K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	69%	237,396	91,086	$11.85M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	18%	225,399	85,425	$3.08M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.5%	135,612	50,582	$942K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	3.6%	6,893	5,291	$614K
99072		1.9%	109,018	41,806	$327K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	4,368	1,936	$164K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	3,644	2,015	$57K
86769		<1%	1,685	1,325	$43K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	2,251	1,009	$12K
86762		<1%	123	122	$1K
99000		<1%	285	212	$930.64
80053	Comprehensive metabolic panel	<1%	268	259	$569.99

11 more codes

85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	93	$440.74
36415	Collection of venous blood by venipuncture	<1%	767	$436.13
80061	Lipid panel	<1%	58	$341.66
83036	Hemoglobin; glycosylated (A1C)	<1%	80	$311.41
84443	Thyroid stimulating hormone (TSH)	<1%	30	$248.52
86592		<1%	35	$131.86
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	28	$124.83
82950		<1%	15	$56.55
81000		<1%	44	$8.84
85652		0%	51	$0.00
86141		0%	53	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHEDGE, DESIREE (PRESIDENT)